Sale of 11,345 IDEXX (NASDAQ: IDXX) shares planned under Rule 144
Filing Impact
Filing Sentiment
Form Type
144
Rhea-AI Filing Summary
A holder of IDEXX Laboratories common stock has filed a notice of proposed sale under Rule 144. The filing covers 11,345 shares of common stock, with an aggregate market value of 7,336,994.15, to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 02/10/2026.
These 11,345 shares were acquired on 02/10/2026 via a stock option exercise from the issuer, paid in cash on the same date. The filing notes that 79,851,330 shares of the issuer’s common stock were outstanding, providing context for the size of the planned sale.
Positive
- None.
Negative
- None.
FAQ
What does the Form 144 filing for IDXX disclose?
The Form 144 shows a planned sale of 11,345 IDEXX common shares under Rule 144. These shares, valued in total at 7,336,994.15, are to be sold on the NASDAQ through Morgan Stanley Smith Barney LLC around 02/10/2026.
Which broker and exchange are involved in the IDXX Form 144 sale?
The planned sale will be executed through Morgan Stanley Smith Barney LLC Executive Financial Services. The Form 144 indicates that the 11,345 IDEXX common shares are intended to be sold on the NASDAQ stock market around 02/10/2026.
What representation does the seller make in the IDXX Form 144?
By signing the notice, the seller represents that they do not know of any material adverse information about IDEXX’s current or prospective operations that has not been publicly disclosed, as required under the Rule 144 filing instructions.